Better Therapeutics (BTTX) Insider Trading & Ownership $0.0001 0.00 (0.00%) (As of 01:57 PM ET) Add Compare Share Share Insider Trades Stock AnalysisChartCompetitorsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsTrends Better Therapeutics (NASDAQ:BTTX) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage51.40%Number OfInsiders Buying(Last 3 Years)9Amount OfInsider Buying(Last 3 Years)$2.30 MNumber OfInsiders Selling(Last 3 Years)0 Get BTTX Insider Trade Alerts Want to know when executives and insiders are buying or selling Better Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address BTTX Insider Buying and Selling by Quarter Ad Colonial MetalsTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersTrump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax Code… And since then… "In the know" patriots have quietly used this same "Trump revenge loophole" to shield their life savings from Bidenomics…Get Your Free Gold Guide Better Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails7/27/2023Andrew J ArmaninoDirectorBuy274,010$0.73$200,027.30 7/27/2023David P PerryChairmanBuy1,233,045$0.73$900,122.85 7/27/2023Frank KarbeCEOBuy137,005$0.73$100,013.65 7/27/2023Mark A BermanInsiderBuy54,802$0.73$40,005.46 5/16/2023Elder GrangerDirectorBuy600$0.87$522.00 4/10/2023Frank KarbeInsiderBuy242,424$0.82$198,787.68 Get Insider Trades Delivered To Your InboxEnter your email address below to receive a concise daily summary of insider buying activity, insider selling activity and changes in hedge fund holdings. 4/10/2023Geoffrey M ParkerDirectorBuy303,030$0.82$248,484.60 9/15/2022Frank KarbeInsiderBuy50,000$2.09$104,500.00 9/12/2022Mark HeinenInsiderBuy23,868$1.94$46,303.92 6/24/2022Mark HeinenInsiderBuy2,281$1.75$3,991.75 6/13/2022Geoffrey M ParkerDirectorBuy25,000$1.45$36,250.00 6/10/2022Mark HeinenInsiderBuy5,000$1.56$7,800.00 3/31/2022Kevin J AppelbaumCEOBuy2,500$1.97$4,925.00 3/31/2022Mark HeinenInsiderBuy5,000$1.98$9,900.00 3/29/2022Andrew J ArmaninoDirectorBuy40,000$2.14$85,600.00 12/21/2021Risa J Lavizzo-MoureyDirectorBuy10,000$4.60$46,000.00 12/20/2021Kevin J AppelbaumCEOBuy1,000$4.60$4,600.00 12/15/2021Kevin J AppelbaumCEOBuy750$4.71$3,532.50 12/15/2021Mark HeinenInsiderBuy2,333$4.70$10,965.10 12/13/2021Andrew J ArmaninoDirectorBuy21,000$5.48$115,080.00 12/13/2021Mark HeinenInsiderBuy500$5.45$2,725.00 12/10/2021Kevin J AppelbaumCEOBuy1,000$5.98$5,980.00 12/3/2021Elder GrangerDirectorBuy1,000$6.66$6,660.00 12/2/2021Kevin J AppelbaumCEOBuy500$6.84$3,420.00 11/29/2021Andrew J ArmaninoDirectorBuy17,000$6.96$118,320.00 (Data available from 1/1/2013 forward) BTTX Insider Trading Activity - Frequently Asked Questions Who is on Better Therapeutics's Insider Roster? The list of insiders at Better Therapeutics includes Andrew J Armanino, David P Perry, Elder Granger, Frank Karbe, Geoffrey M Parker, Kevin J Appelbaum, Mark A Berman, Mark Heinen, and Risa J Lavizzo-Mourey. Learn more on insiders at BTTX. What percentage of Better Therapeutics stock is owned by insiders? 51.40% of Better Therapeutics stock is owned by insiders. Learn more on BTTX's insider holdings. Which Better Therapeutics insiders have been buying company stock? The following insiders have purchased BTTX shares in the last 24 months: Andrew J Armanino ($200,027.30), David P Perry ($900,122.85), Elder Granger ($522.00), Frank Karbe ($298,801.33), Geoffrey M Parker ($248,484.60), and Mark A Berman ($40,005.46). How much insider buying is happening at Better Therapeutics? Insiders have purchased a total of 2,244,916 BTTX shares in the last 24 months for a total of $1,687,963.54 bought. Better Therapeutics Key ExecutivesMr. David P. Perry M.B.A. (Age 56)Co-Founder & Executive Chairman Compensation: $260kMr. Frank L. Karbe (Age 56)CEO, Interim CFO, President & Director Compensation: $533.37kDr. Mark A. Berman M.D. (Age 48)Chief Medical Officer Compensation: $573.75kMs. Kristin Wynholds (Age 51)Chief Product Officer Compensation: $519.07kMr. Andres CamachoSenior VP of Technology & Head of EngineeringMs. Angela WillisSenior Vice President of Market AccessMs. Jessica MengChief Commercial OfficerLeslie MillerController More Insider Trading Tools from MarketBeat Related Companies AONC Insider Trades LFMDP Insider Trades TOIIW Insider Trades BFI Insider Trades NTRA Insider Trades FMS Insider Trades HIMS Insider Trades GH Insider Trades OPCH Insider Trades SHC Insider Trades Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Insiders Selling Into 3 Rallies: Investors Should Do the OppositeInsiders Bet Big on These Small Cap StocksHere’s Why Etsy Management Is Investing $1 Billion in BuybacksInsider Buying Signals Upside for These 3 StocksBig Buybacks Announced: 3 Stocks Insiders Are Banking On This page (NASDAQ:BTTX) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Better Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Better Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
